3,4-dimethyl-3H-thieno[2,3-b]pyrazine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3,4-dimethyl-3H-thieno[2,3-b]pyrazine
• 化学式: C₈H₁₀N₂S
• 分子量: 166.25
• InChiKey: VGWKTDBCRAETJJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  43.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• DIRECT CH ARYLATION METHOD USING PALLADIUM-BASED CATALYST
  申请人：Lee Jae-Suk

  公开号：US20140142263A1

  公开（公告）日：2014-05-22

  Disclosed herein is a first example of effective direct position specific C—H arylation of thieno[3,4-b]pyrazine derivative and several hetero aryl bromide under the ‘Heck-type’ experiment condition using Pd(OAc) 2 /n-Bu4NBr as a catalyst system, thienopyrazine in which aryl is replaced to increase various values. The current synthesis methodology is a simpler method than a facial method and is used to prepare π-conjugated oligomer and/or polymer material based on interesting hexylthiophen and thienopyrazine portion for electronic industries which construct a new synthetic organic material using potential application programs. The arylation generates more position selectivity in a C—H bond than in a pyrazine C—H bond. The optical and electrical characteristics of the synthesis copolymer are survey.

  本文披露了一种有效的直接位置特异性C-H芳基化噻吩[3,4-b]吡嗪衍生物和几种杂环芳基溴化物的第一个例子，在Pd（OAc）2 / n-Bu4NBr作为催化体系的“Heck型”实验条件下，将芳基替换为增加各种价值的噻吩吡嗪。当前的合成方法比面部方法更简单，并用于制备基于有趣的己基噻吩和噻吩吡嗪部分的π共轭寡聚物和/或聚合物材料，用于电子工业，构建使用潜在应用程序的新型合成有机材料。芳基化在C-H键中产生比在吡嗪C-H键中更多的位置选择性。调查了合成共聚物的光学和电学特性。
• INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20140142115A1

  公开（公告）日：2014-05-22

  This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.

  本发明涉及具有结构式I的化合物及其药学上可接受的盐，这些化合物是肾外髓质钾通道（Kir1.1）的抑制剂。公式I的化合物可用作利尿剂和钠利尿剂，因此可用于治疗和预防由过度盐和水潴留引起的疾病，包括高血压和慢性和急性心力衰竭等心血管疾病。
• US9040655B2
  申请人：——

  公开号：US9040655B2

  公开（公告）日：2015-05-26